Evaluating the Impact of Breastfeeding on Rotavirus Antigenemia and Disease Severity in Indian Children

Sushmita Das¹*, Ganesh Chandra Sahoo², Pradeep Das², Utpal Kant Singh³, Anil Kumar Jaiswal³*, Prachi Singh³, Ranjeet Kumar², Rishikesh Kumar²

¹ Department of Microbiology, All-India Institute of Medical Sciences (AIIMS), Patna, India, ² Virology Unit, Rajendra Memorial Research Institute of Medical Sciences (ICMR), Patna, India, ³ Department of Paediatrics, Nalanda Medical College and Hospital, Patna, India

* Current address: Department of Paediatrics, Patna Medical College and Hospital, Patna, India.
* sushmita.de2008@gmail.com

Abstract

Objectives

To evaluate the contribution of breastfeeding to Rotavirus (RV)-induced antigenemia and/or RNAemia and disease severity in Indian children (<2 yrs age).

Methods

Paired stool and serum samples were collected from (a) hospitalized infants with diarrhea (n = 145) and (b) healthy control infants without diarrhea (n = 28). Stool RV-antigen was screened in both groups by commercial rapid-test and enzyme immunoassay. The disease severity was scored and real-time-PCR was used for viral-load estimation. Serum was evaluated for RV-antigenemia by EIA and RV-RNAemia by RT-PCR. Data was stratified by age-group and breastfeeding status and compared.

Results

Presence of RV-antigenemia and RV-RNAemia was positively related with presence of RV in stool. Disease severity and stool viral-load was significantly associated with RV-antigenemia[(r = 0.74; CI:0.66 to 0.84; P<0.0001,R² = 0.59) and (r = -0.55; CI:-0.68 to -0.39; P<0.0001,R² = 0.31) respectively], but not with RV-RNAemia. There was significant reduction in RV-antigenemiarate in the breast-fed group compared to non-breastfed infants, especially in 0–6 month age group (P<0.001). Non-breastfed infants were at risk for RV-antigenemia with severe disease manifestations in form of high Vesikari scores correlating with high fever, more vomiting episodes and dehydration.

Conclusion

RV-antigenemia was common in nonbreastfed children with severe RV-diarrhea and correlated with stool RV-load and disease severity.
Introduction

Rotavirus (RV) is the major worldwide cause of acute gastroenteritis (AGE) with severe dehydrating diarrheain children below 5 years [1]. WHO estimates that RV is responsible for 40% of AGE amongst children (<5 years) and causes 453,000 deaths annually in children under 5 years worldwide, predominately in low-income countries. Currently, two live oral vaccines (RV1; Rotarix and RV5; RotaTeq™) are licensed worldwide [2,3].

The RV belongs to family Reoviridae and generally infectsthevillus enterocytes [4]. However, extraintestinal case reports challenges this concept [5]. Antigenemia, a common phe-

nomenon detected in RV-infected children, is characterized by transient presence of antigen in the blood [6–8] and could explain the mechanism for extraintestinal RV infections. Detection of serum rotavirus antigen ranges from 43–90% in acute phase of the infection. However, the phase of antigenemia is transient as peak levels of RV-antigen are usually seen during early days of infection and are undetectable beyond a week. Simultaneously, RV-RNAemia (presence of RV-RNA in blood) has also been reported earlier [6]. Interestingly, several stud-

ies have attempted to find rotavirus RNA/nonstructural proteins from extraintestinal samples [5–7].

The current WHO guidelines recommend continued breastfeeding during diarrhea manage-

ment [9]. However, protective role of breastfeeding in RV-diarrhea has been questioned [10,11]. Lower immunogenicity and efficacy of the RV vaccines has been demonstrated in lower income countries in Africa and Asia, compared to high income countries. Of interest, studies support that low immunogenicity of RV-vaccines could be due to higher titers plus neutralizing activity of RV-specific-IgA and other nonspecific inhibitors in breast milk consumed by infants at the time of immunization [11, 12]. Nevertheless, correlation of breastfeeding with systemic manifestations of RV-antigenemia/RV-RNAemia and disease severity in rotavirus-positive patients has not been studied in the Indian population.

Patients and Methods

Subjects and sample collection

We have enrolled peri-urban patients <2 years with AGE, attending paediatric facilities either at Nalanda Medical College, Patna or Child Care Center, Patna, Bihar for 2 consecutive years. A total of 173 paired stool and serum samples were collected from immunocompetant, non-RV-vaccinated children; among which 145 were from hospitalised infants with diarrhreaand 28 were from age-sex matched healthy infants with no symptoms of diarrheaduring the last 2 weeks before collection (S1 Table). Inclusion criteria for symptomatic cases included passing of ≥3 loose/watery stools within 24 hours and satisfied with one of the fol-

lowing criteria for moderate to severe diarrhea (MSD) viz. a) sunken eyes (confirmed by par-

ent/caretaker); b) skin turgor-loss defined as an abdominal skin pinch with slow or very slow (<2 seconds) recoil; c)intravenous hydration administered/prescribed; d) hospitalization with diarrheaoa dysentery. The healthy control group consisted of children who were not suf-

fering from diarrhea before 14 days of case recruitment. Stool/rectal swab samples from all diarrhoeal children were screened for RV. The patients with mixed infections with other enteric viruses/bacteria/parasites were excluded from the study. Two blood samples were retrospecively collected from RV-positive patients: the first within 3 days after admission (acute phase) and the second after 3 weeks of admission (convalescent phase); the serum samples were prepared for further analysis. Extra intestinal presentations were recorded wherever available.
Ethics statement
The study was performed in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Institutional Review Board, Rajendra Memorial Research Institute of Medical Sciences, Patna. Paired serum and stool specimens were collected after obtaining written informed consent of the parent or guardian prior to enrolling a child. The potential controls were randomly selected from the population and matched to the cases by age, gender, and residence (same/nearby neighbourhood area as the case). A standard questionnaire was used to collect general, demographic, epidemiological and clinical data.

Assessment of disease severity
Diarrhea was defined as the passage of ≥3 watery stools in a 24-h period [13]. Clinical severity of RV-AGE was assessed by examination of the child and interview of the mother/caregiver by the study paediatrician using the 20 point scale of the Vesikari scoring system [14], based on the frequency and severity of diarrhoea, daily frequency of vomiting, episodes of fever and degree of dehydration. As per the scoring protocol, the episode was considered mild for a score of ≤5, moderately severe for a score of 6–10, and severe for a score of >10.

Data stratification
We stratified infants, of all groups, by their age. Age stratification was done as follows; Group A: 0–6 months (age of exclusive breastfeeding), Group B: 6–12 months (age of breastfeeding + weaning) and Group C: 13–24 months (age of gradual changeover to adult-like family food). In all groups, infants receiving breast milk during/before their current episode of diarrhea were defined as breastfed and those not receiving any amount of breast milk represented as non-breastfed infants.

Detection of RV in stool
Preliminary screening of the collected stool samples for the presence of RV coproantigen was performed using Rota-Adeno RDT kit as per the manufacturer’s instructions (VIKIA® R, Rota-Adeno, Biomerieux®). Next, for further confirmation, the stool samples were tested for RV by commercial enzyme immunoassay (EIA) Premier™ RotaClone (Meridian Bioscience Inc., Cincinnati, OH, USA), according to the manufacturer’s instructions. Samples with optical densities > set cut-off point were considered positive while optical densities ≤ set cut-off point were taken as negative.

Viral RNA extraction
From the positive samples, 20% fecal suspensions were used for viral RNA isolation using commercial RNA extraction kit (QIAamp viral RNA MiniKit, Qiagen, Germany) according to manufacturer’s instructions. Complementary DNA (cDNA) was synthesized using random primers (Invitrogen, Life Technologies, USA) and Moloney-Murine-Leukemia-Virus Reverse Transcriptase (M-MLVRT) (Invitrogen, Life Technologies, USA) [15].

Estimation of viral load in stool
The test cDNA prepared from stool samples were used to estimate viral load in stool by a Real-time RT-PCR method [16]. Briefly, the stool RV-cDNA was used in the VP6-specific real-time PCR using the LightCycler™ (Roche, Germany) with SYBR green-dye and primers [VP6-F (5’GACGGVGRCTACATGGTT3’); VP6-R (5’GCAAATCCTNGCTTGG3’)] resulting in a...
379-bp product. RV-load in stool samples was estimated in terms of the PCR cycle or crossing point (C[t] value) and specificity was measured by melting curve analysis.

Detection of rotavirus antigen and RNAemia in serum specimens

Serum samples retrospectively collected from the RV-positive patients, were screened by EIA for RV-antigenemia and by RT-PCR for RV-RNAemia according to reported methods [6,7,17]. Briefly, undiluted serum specimens (50μL) were tested for RV antigen in serum using Premier™RotaClone kit. A modified optical density (OD) cutoff value of 0.3 was read at 450 nm wavelength for serum RV-antigen detection [7]. An absorbance OD > cutoff value of 0.3 was defined as RV-antigenemia. Levels of RV-antigenemia were normalized for interassay variability against the mean OD value for the negative control serum samples. Simultaneously, RV-RNAs were extracted from the serum specimens by using a High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Germany) according to the manufacturer’s protocol. Then, reverse transcription of RV-RNA was performed using Superscript III Reverse Transcriptase (Invitrogen Corporation, USA). The VP7-1’ and Beg9 primers selected for the partial sequence of the VP7 gene were studied [18]. The complimentary DNA was amplified with 0.2U Taq DNA polymerase (Fermentas) in 25 μl reaction under the following conditions: initial incubation at 94°C(3min), followed by 35 cycles at 94°C (30sec), annealing at 55°C (30 sec) and extension at 72°C (1min), with a final extension at 72°C (7min). The 395-bp products were checked in 2% agarose gel electrophoresis, densitometrically scanned (Quantity-One software; Bio-Rad, USA) and normalized to GAPDH expression.

Statistical analysis

All statistical analyses were performed using GraphPad PRISM5 Software and comparisons were based on the Mann–Whitney U-test or one-way analysis of variance (ANOVA) with a post hoc test. Spearman’s rank correlation and Linear regression were used to assess the correlations. The Pearson correlation was used for data that displayed Gaussian distribution.

Results

Prevalence, clinical symptoms and epidemiology in AGE patients

Among 145 faecal samples, 94 (64.8%) were RV-positive and 51 were RV-negative (35.1%). A total of 102 (70.3%) children represented with fever >37°C, 82 (56.5%) with mild/severe dehydration, and 124 (85.5%) with vomiting episodes. Extra intestinal presentations were recorded in 32 diarrheal infants. The Vesikari 20 point scale scoring system for the severity of disease rated the symptomatic children with median value of 10, while healthy children were assigned a score of 0. Diarrhoeal episodes had lasted >4 days in 40% of children at the time of admission. Treatment regime with intravenous rehydration followed by oral rehydration was followed for 98 (67.5%) children, whereas 47(32.5%) had received only oral rehydration.

A distinct seasonal variation in RV prevalence was observed, with low levels of positivity (10–20%) throughout the year and surge (75–80%) during the winter months in November to February (Fig 1A). Mostly, children <1 yr age were affected by RV (Fig 1B).

Breastfeeding Vs Rotavirus antigenemia/RNAemia in children

Among the total 145 infants with diarrhea, the prevalence of breastfed infants was 23.4% (34 children) compared to 76.5% (111 children) prevalence of non-breastfed ones (Fig 2A, S1 Table). Notably, RV-diarrhea was most common among the latter group (Fig 2A, S1 Table).
First, the prevalence of RV-diarrhea was observed in the stool samples among the age stratified children groups. In the breast-fed group, RV diarrhea was higher (57%) in the 7–12 months age group compared to the prevalence in other two groups of infants; aged 0–6 months (20%) and 13–24 months (23%) (Fig 2B). Conversely, among the non-breastfed infants, the prevalence of RV-diarrhea was highest (76%) among 0–6 months old group compared to groups of 7–12 months age (18%) and 13–24 months age (6%) (Fig 2B).

Next, the prevalence of RV-diarrhea was observed in the serum samples among infants, with respect to their feeding status. Among the breastfed infants, serum of 21% and 46% presented positivity for RV-antigenemia and RV-RNAemia respectively (Fig 2C). Contrastingly, in non-breastfed, serum of 36% and 54% presented positivity for RV-antigenemia and RV-RNAemia respectively (Fig 2C). It is important to note that RV-antigenemia levels were significantly high among non-breastfed infants (Fig 2D and 2E).

Rotavirus antigenemia in Indian children

The serum VP6 antigen was identified in 67 (71.2%) of 94 RV-positive and in only 3 (5.8%) of 51 RV-negative cases (Fig 3A). Therefore, as reported [19], RV-antigenemia was significantly higher among RV-positive cases (p<0.001). Of note, none of the convalescent phase serum, from 94 RV-positive and 51 RV-negative cases, showed positivity for RV-antigenemia (Fig 3B and 3C).
Rotavirus RNAemia in Indian children

RV-RNAemia was detected in acute-phase serum of 77 (81.9%) out of 94 RV-positive cases and 2 (3.9%) out of 51 RV-negative cases. (Fig 4A and 4B). Interestingly, some patients with RV-positive diarrhea had confirmatory RT-PCR results for RV-RNAemia, but was negative for RV-antigenemia. RV-antigenemia levels were insignificant in the convalescent phase serum compared to their levels in the acute phase (Fig 3B). However, detectable levels of RV-RNAemia was found in the convalescent phase serum of 79 (84.04%) out of 94 RV-positive cases and 2 (3.9%) out of 51 RV-negative cases (Fig 4B). These two children, with RV-negative stool in EIA, presented positivity for both RV-antigenemia and RV-RNAemia.

Correlation of Rotavirus antigenemia with stool viral-RNA load and disease severity

Next, we compared the RV-antigenemia levels in patient serum (acute and convalescent) with viral load result in paired stool samples. The stool viral load result correlated well with levels of RV-antigenemia, i.e. majority of patients with RV-antigenemia results in acute sera (71.2%) had positive RT-PCR results in stool (r = -0.55; CI = -0.68 to -0.39; P < 0.0001, R² = 0.31; Fig 5A), but not in convalescent-phase patient sera (r = 0.019; CI = -0.18 to 0.22; P = 0.85, R² = 0.0003, Fig 5B). The healthy control individuals were uniformly negative by RT-PCR as well as serum EIA. Interestingly, RV-RNA was not found in stool of 3 children out of 51 RV-negative cases, who were also positive for RV-antigenemia.

Disease severity plus high levels of RV-antigenemia was recorded in 29 RV-EIA positive infants (30.8%), with Vesikari scores ranging from 9–12 compared whereas low levels of
RV-antigenemia showed Vesikari scores ranging from 0–8. Only one patient, reporting intermittent convulsions in the severe group, also presented with high levels of RV-antigenemia. Therefore, disease severity was positively correlated with RV-antigenemia ($r = 0.74$, $P < 0.0001$, $R^2 = 0.59$; Fig 6A). Of interest, all the infants with high levels of RV-antigenemia and high Vesikari scores were from the non-breastfed group. Extra-intestinal presentation data was analysed for 32 infants and we found that majority of the patients presented with respiratory tract infections (RTI; 18 with upper RTI and 5 with lower RTI). Only 9 out of 32 patients, with extra-intestinal symptoms, also presented with RV-antigenemia.

**Fig 3. Rotavirus antigenemia levels among the study groups.** (A-C) Data demonstrates level of Rotavirus antigenemia in acute-phase (A) and convalescent phase (B) sera in infants suffering from severe diarrhea in comparison with the healthy control group. Paired acute-phase and convalescent phase sera were tested for Rotavirus antigenemia levels, that is denoted by levels of Rotavirus antigen (optical density/O.D.) measured by RV-EIA at 450 nm X 1000 units, as mentioned in the text. Broken lines denote the cut-off value.

doi:10.1371/journal.pone.0146243.g003
Correlation of Rotavirus RNAemia, stool viral RNA load and disease severity

No significant correlation was found for RV-RNAemia positivity in acute (r = -0.07; CI = 0.29 to 0.14, P = 0.5; Fig 5C) or convalescent sera (r = -0.10; CI = -0.32 to 0.12, P = 0.3; Fig 5D) with stool viral RNA load. Among the 12 infants who were detected positive for RV-RNAemia, five also presented with disease severity, i.e. Vesikari score >10. However, none of the infants, positive for only RV-RNAemia, presented severity of diarrheal symptoms in terms of Vesikari scores (range: 0–10), in comparison to patients with RV-antigenemia. Therefore, disease severity was not significantly correlated with RV-RNAemia (r = 0.7443, P<0.0001, R2 = 0.5996; Fig 6B).
Disease severity was related to breast feeding status of the infants

We stratified the data of disease severity according to the breastfeeding status of the infants suffering from AGE with diarrhea. Notably, we found that disease severity was related to breastfeeding habit as the median Vesikari score was high among the non-breastfed group (Fig 6C; S1 Table).

**Discussion**

The association between breast feeding and infants health has been noted over past several years. Bioactive components of the human milk either protect from specific pathogens or families of pathogens or confer mucosal immunity to the infant. The present hospital based
age-matched case-control study was taken up to analyze the clinical significance of rotavirus antigenemia/RNAemia and disease severity with respect to breastfeeding in Indian infants. Though breastfeeding is recommended during diarrhea management, its protective role in rotaviral diarrhea has been questioned [10]. Antigenemia was earlier reported among Indian children [19], but RV-RNAemia/ RV-antigenemia and disease severity were not evaluated in the context of breastfeeding in the population. In this study, we have enrolled children (<2 yrs age), presenting with AGE and diarrhea, from two tertiary-care hospitals in Bihar, North India (S1 Table). To the best of our knowledge, till date no study has reported AGE with rotavirus infection and its correlation with breastfeeding status of infants in Bihar.
In our study, the rate of RV-antigenemia in the acute-phase serum of RV-positive infants was higher to that of previous studies that ranged from 43%–75% of children with rotavirus AGE [7,19,20]; but was lower than a recent report of 90% [6]. The differences of RV-antigenemia in the reports may be due to the chosen study populations, level of anti-RV IgG, days from onset of diarrhea or the variation between the times of serum collection. Interestingly, it was reported that RV-antigenemia is inversely associated with baseline titres of serum rotaviral-IgG [20]. Additionally, detection of RV-antigenemia also depends on level of viral antigen in the stool [7] and when the blood was drawn [7,17,21,22]. Therefore, the high frequency of RV-antigenemia in our study probably reflects high prevalence of the virus among infants in this zone, high sensitivity of the method used to detect RV-antigenemia in the test samples and/or low transfer of maternal rotaviral serum IgG to the child. Notably, RV-antigenemia was also detected in 5.8% children with RV-EIA negative stool samples. This could imply several possibilities, viz. a) false-negative stool RV-EIA result, b) false-positive RV-antigenemia result and/or c) RV-antigenemia may not require excretion of the virus/viral antigen in stool. As none of the healthy infants without diarrhea showed positivity for RV-antigenemia, a false-positive result in serum is quite unlikely. It could be postulated that RV-antigenemia does not relate to presence of EIA detectable RV-antigen in the stool.

All RV-EIA negative, but RV-antigenemia positive infants, demonstrated negative results for viral load RT-PCR in stool. Therefore, all of these 3 infants may have past asymptomatic RV infection with undetectable virus or viral antigen in the stool. Interestingly, 28.7% infants were positive for both RV-EIA and RV viral load RT-PCR, but were negative for RV-antigenemia. Therefore, viral antigen or RNA in stool is not always required for RV-antigenemia. Of note, disease severity was associated with RV-antigenemia, as high Vesikari scores was positively related with high levels of RV-antigenemia, but not with RV-RNAemia. Notably, RV-antigenemia level is reported to be directly associated with stool antigen levels but inversely related to specific anti-rotavirus antibodies titres in the serum [17,20].

Immunity induced by natural symptomatic or asymptomatic RV infection can protect from symptomatic RV disease [23]. However, RV-antigenemia and RV-RNAemia indicate induction of both mucosal as well as systemic immune response [5,6,17]. Therefore, considering testing of serum of RV-EIA positive patients for RV-antigenemia may be an additive measure to clinically evaluate the disease. However, our findings indicate that, disease severity and stool viral load is positively related with RV-antigenemia, but not with RV-RNAemia.

In this study, we have attempted to evaluate the correlation of breastfeeding with systemic spread of RV in the form of RV-antigenemia RV-RNAemia in infants with AGE-diarrhea in Bihar, India. The passive protective effect of maternal antibodies, transferred through placenta or through breast milk, may have role against RV infection, at least during early months of breastfeeding [23]. Our results showed that 76.5% of the infants with AGE-diarrhea were from the non-breastfed group and 72% among them presented with RV-antigenemia. Previous report from India demonstrated that, infants whose mothers had high titres of anti-RV-IgA in breast milk remain less affected by RV disease compared to those with low titres of anti-RV-IgA [24]. In a cohort study in Mexico, the serum anti-RV-IgA titre of >1:800, but not high levels of serum anti-RV-IgG, induced 80% protection against the disease [25]. As RV-antigenemia is inversely associated with baseline titres of rotaviral serum IgG in Indian children [20], findings of high rates of RV-antigenemia and RV-RNAemia in nonbreastfed children in the 0–6 months age group may probably reflect low transfer of maternal rotaviral serum IgG to the child through breast milk.

Interestingly, breast milk also contains bioactive components viz. lactoferrin, lactadherin, secretory IgA, lymphocytes, oligosaccharides [26] and human milk glycans [27,28]. Several milk components have crucial nutrients, whose partially digested forms have anti-pathogenic
effects and are part of the innate immunity. Two such components are (a) human milk triglycerides and (b) lactoferrins. Interestingly, antimicrobial peptides are abundant in human milk and confer innate protection in the mucosal environment [29, 30]. Lactadherin, a milk-fat globule membrane (MFGM) glycoprotein, has been reported to prevent symptomatic RV infection [29] while the anti-RV antibodies in human milk may also have some role [31]. Exclusive breastfeeding was found to be associated with a lower incidence of RV gastroenteritis [32], non-breastfed infants are therefore vulnerable to RV infections [33]. Interestingly, unlike the human ones, bovine lactadherin is not active against Rotavirus infection [34]. Notably, many human rotaviruses contain a special Asp-Gly-Glu (DGE) motif in VP8 which is required for their adhesion to host integrins establish the infection [33]. Lactadherins competitively bind with the integrin receptors and prevent RV infection. RV-antigenemia/RV-RNAemia is the systemic spread of the RV leading to severe extra-intestinal complications [5]. Therefore, human breast milk may play a protective role in breastfed infants against spread of RV-antigenemia/RV-RNAemia and subsequent disease severity.

Reports also suggest that protection against RV disease can be conferred by neutralizing antibodies in serum [35]. Previous reports have suggested the presence of anti-RV-IgA and neutralizing antibodies in breast milk [36]. We demonstrated that RV-diarrhea was mostly common among the non-breastfed infants, prevalently (76%) in the 0–6 month age group. Studies with oral RV-vaccine indicated that breast-feeding had effects on vaccine efficacy [37]. Although the mechanism of potential suppression of vaccine efficacy by breast milk is debatable; neutralizing antibodies, lactoferrin and lactoadherin might have a prominent role [38,39]. High Vesikari scores among non breastfed infants (Fig 6C) suggest a protective role of breastfeeding during the early months in infants.

Proper breastfeeding promotion campaigns and counselling programmes are needed to be initiated, especially in low-income countries. Our results are more pertinent from the standpoint of worldwide introduction of live oral rotavirus vaccines and its efficacy in relation to breastfeeding.

Supporting Information
S1 Table. Characteristics of the study subjects with acute gastroenteritis and diarrhea.
(DOCX)

Acknowledgments
We thank Mr. Subhash Kumar and Ms. Bhawana Singh for the technical assistance.

Author Contributions
Conceived and designed the experiments: SD PD GCS. Performed the experiments: SD PS RK RSK GCS. Analyzed the data: SD PD UKS AKJ. Contributed reagents/materials/analysis tools: PD UKS AKJ. Wrote the paper: SD PD.

References
1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. WHO coordinated Global Rotavirus Surveillance Network: 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(2): 136–41. doi: 10.1016/S1473-3099(11)70253-5 PMID: 22030330
2. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Costa-Clemens SA, et al., Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354 (1):11–22. PMID: 16394298
3. Heaton PM, Ciarlet M. The pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 2007; 45(12):1618–1624. doi: 10.1086/522997 PMID: 18198497

4. Matthijnssens J, Ciarlet M, Rahman M, Attoui H, Bányai K, Estes MK et al. Recommendations for the classification of group A rotavirus using all 11 genomic RNA segments. Arch Virol 2008; 153(8):1621–1629. doi: 10.1007/s00705-008-0155-1 PMID: 18604469

5. Blutt SE, Conner ME. Rotavirus: to the gut and beyond! CurrOpinGastroenterol 2007; 23(1):39–43.

6. Blutt SE, Matson DO, Crawford SE, Staat MA, Azimi P, Bennett BL et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007; 4(4):e121. PMID: 17439294

7. Fischer TK, Ashley D, Kerin T, Reynolds-Hedmann E, Gentsch J, Widdowson MA et al. Rotavirus antigenemia in patients with acute gastroenteritis. J Infect Dis 2005; 192(5):913–919. PMID: 16088842

8. Fujita Y, Liu B, Kohira R, Fuchigami T, Mugishima H, Izumi H et al. Rotavirus antigenemia and genomics in children with rotavirus gastroenteritis. Jpn J Infect Dis 2010; 63(2):83–86. PMID: 20332567

9. Morrow AL, Rangel JM. Human milk protection against infectious diarrhea: implications for prevention and clinical care. SeminPediatr Infect Dis 2004; 15(4):221–228.

10. Glass RI, Stoll BJ, Wyatt RG Hoshino Y, Banu H, Kapikian AZ. Observations questioning a protective role for breast-feeding in severe rotavirus diarrhea. ActaPaediatrScand 1986; 75(5):713–718.

11. Clemens J, Rao M, Ahmed F, Ward R, Huda S, Chakraborty J et al. Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement? Pediatrics 1993; 92(5):680–685. PMID: 8414854

12. Nelson EA, Glass RI: Rotavirus: realising the potential of a promising vaccine. Lancet 2010; 376(9741):568–570. doi: 10.1016/S0140-6736(10)60896-3 PMID: 20692032

13. Morris SS, Cousens SN, Lanata CF, Kirkwood BR. Diarrhoea—defining the episode. Int J Epidemiol 1994; 23(3):617–623. PMID: 7960391

14. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22(3):259–267. PMID: 2371542

15. Iturriza-Gomara M, Green J, Brown DW, Desselberger U, Gray JJ. Comparison of specific and random priming in the reverse transcriptase polymerase chain reaction for genotyping group A rotaviruses. J Virol Methods. 1999; 78(1–2):93–103. PMID: 10204700

16. Iturriza-Gomara M, Wong C, Chirmack T, Desselberger U, Gray J. Molecular characterization of VP6 genes of human rotavirus isolates: Correlation of genogroups with subgroups and evidence of independent segregation. J Virol. 2002; 76(13):6596–6601. PMID: 12050372

17. Blutt SE, Kirkwood CD, Parreno V, Warfield KL, Ciarlet M, Estes MK et al. Rotavirus antigenemia and viraemia: a common event? Lancet 2003; 362(9394):1445–1449. PMID: 14602437

18. Phan TG, Khamrin P, Quang TD, Dey SK, Takanashi S, Okitsu S et al. Detection and genetic characterization of group A rotavirus strains circulating among children with acute gastroenteritis in Japan. J Virol 2007; 81(9):4645–4653. PMID: 17301134

19. Ramani S, Paul A, Saravananavaran A, V K, Arumugam R, Sowmyanarayanan TV et al. Rotavirus antigenemia in Indian children with rotavirus gastroenteritis and asymptomatic infections. Clin Infect Dis. 2010; 51(11):1284–1289. doi: 10.1086/657069 PMID: 21039217

20. Ray P, Fenaux M, Sharma S, Malik J, Subodh S, Bhatnagar S et al. Quantitative evaluation of rotavirus antigenemia in children with acute rotavirus diarrhea. J Infect Dis 2006; 194(5):588–593. PMID: 16897656

21. Sugata K, Taniguchi K, Yui A, Miyake F, Suga S, Asano Y et al. Analysis of rotavirus antigenemia and extraintestinal manifestations in children with rotavirus gastroenteritis. Pediatrics 2008; 122(2):392–397. doi: 10.1542/peds.2007-2290 PMID: 18676558

22. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335(14):1022–1028. PMID: 8793926

23. Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. MucosalImmunol 2015; 8(1):1–17.

24. Jayashree S, Bhan MK, Raj P, Kumar R, Svensson L, Stintzing G et al. Neonatal rotavirus infection and its relation to cord blood antibodies. Scand J Infect Dis 1988; 20(3):249–253. PMID: 3406664

25. Velazquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182(6):1602–1609. PMID: 11069230

26. Morrow AL, Ruiz-Palacios GM, Altmay E, Jiang X, Guerrero ML, Meinzen-Derr JK et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr 2004; 145(3):297–303. PMID: 15343178
27. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005, 25:37–58. PMID: 16011458
28. Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J Nutr 2005, 135(5):1304–1307. PMID: 15867329
29. Newburg DS, Peterson JA, Ruiz-Palacios GM, Matson DO, Morrow AL, Shults J, et al. Role of human milk lactadherine in protection against symptomatic rotavirus infection. Lancet 1998; 351: 1160–1164. PMID: 9643686
30. Phadke SM, Deslouches B, Hileman SE, Montelaro RC, Wiesenfeld HC, Mietzner TA. Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr. 2005, 135: 1289–1293. PMID: 15867326
31. Asensi MT, Martinez-Costa C, Buesa J. Anti-rotavirus antibodies in human milk: quantification and neutralizing activity. J PediatrGastroenterolNutr 2006, 42(5):560–567.
32. Prameela KK and Vijaya LR. The importance of breastfeeding in rotaviral diarrhoeas. Malas J Nutr2012, 18: 103–111.
33. Civra A, Giuffrida AG, Donalisio M, Napolitano L, Takada Y, Coulson BS, et al. Identification of Equine Lactadherin-derived peptides that inhibit rotavirus infection via integrin receptor competition. J Biol-Chem2015, 290(19):12403–124014.
34. Kvistgaard AS, Pallesen LT, Arias CF, Lopez S, Petersen TE, Heegaard CW, et al. Inhibitory effects of human and bovine milk constituents on rotavirus infections. J Dairy Sci2004, 87: 4088–4096.
35. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis2002; 34(10):1351–1351. PMID: 11981731
36. Brussow H, Benitez O, Uribe F, Sidoti J, Rosa K, Cravioto A. Rotavirus-inhibitory activity in serial milk samples from Mexican women and rotavirus infections in their children during their first year of life. J ClinMicrobiol 1993; 31(3), 593–597.
37. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354(1): 23–33. PMID: 16394299
38. Moon SS, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010; 29(10): 919–923 doi: 10.1097/INF.0b013e3181e232ea PMID: 20442687
39. Moon SS, Tate JE, Ray P, Dennehy PH, Archary D, Coutsoudis A, et al. Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J 2013; 32(8): 863–870. doi: 10.1097/INF.0b013e318290646d PMID: 23584581